Almoustapha Mahamane Wazodan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Almoustapha Mahamane Wazodan has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Léon Gueswendé Blaise Savadogo
Université Nazi Boni, Institut supérieur des sciences de la santé (INSSA), Burkina Faso
3 shared publications Ibrahim Alkassoum
Niamey Faculty of Health Sciences of Abdou Moumouni University
2 shared publicationsMoustapha M. Lamine
Department of Biological Science Lab-EGB2S Zinder Université André Salifou
2 shared publications- Alkassoum Salifou Ibrahim
Département de Santé Publique, Université Abdou Moumouni, FSS, Niamey, Niger
1 shared publication Mahamadou Doutchi
Département de Médecine et Spécialités Médicales, Faculté des Sciences de la Santé, CFRMT-UAM, Université André Salifou Zinder, Niger
1 shared publicationMahaman Moustapha Lamine
Université André Salifou Zinder, Département des Sciences Biologiques, Lab-EGB2S, CFRMT-UAM, Niger
1 shared publication
Latest Publications
- Open Access
- 18 May 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 539
Study of the coverage and the impact of the chemoprevention of seasonal malaria in Niger from 2013 to 2022: systematic review
Purpose Malaria remains a public health problem in Niger, especially among children under the age of five. To combat this scourge, since 2012, the World Health Organization (WHO) has recommended seasonal malaria chemoprevention (SMC), a strategy based on the administration of sulfadoxine-pyrimethamine and amodiaquine (SP-AQ) during the period of high transmission. This systematic review assesses the coverage, efficacy, and challenges of SMC in Niger between 2013 and 2022, analyzing its impact on malaria morbidity and mortality. Materials and methods The PRISMA guidelines were used to ensure a rigorous and comprehensive recording of the systematic review process. Through searches in five different databases, articles were imported into Zotero software, then transferred to the Covidence application, where data processing was carried out. The selected articles were independently evaluated by two reviewers. These included studies that assessed coverage, malaria incidence, and the impact of SMC. Studies published in French and English were included. Data extraction from the included studies was performed, and a quality assessment was conducted, including an evaluation of the risk of bias. Results Among the six studies, three assessed SMC coverage in all eight regions of Niger while also evaluating side effects. They showed high overall coverage but low coverage in some areas. Another study examined the impact in terms of the incidence of complicated malaria, malaria-related hospitalization, and mortality. Another publication revealed that antibody responses against the blood and pre-erythrocytic stages of P. falciparum were higher in the area where SMC was implemented. Conclusions This study demonstrates that SMC has a significant impact on reducing malaria incidence. Although there is high overall coverage, variations exist, particularly in hard-to-reach areas. Few adverse events were reported. However, very few studies are available, highlighting the need for additional research in Niger to better understand this strategy.
- 18 May 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 539
Open AccessStudy of the coverage and the impact of the chemoprevention of seasonal malaria in Niger from 2013 to 2022: systematic review
Purpose Malaria remains a public health problem in Niger, especially among children under the age of five. To combat this scourge, since 2012, the World Health Organization (WHO) has recommended seasonal malaria chemoprevention (SMC), a strategy based on the administration of sulfadoxine-pyrimethamine and amodiaquine (SP-AQ) during the period of high transmission. This systematic review assesses the coverage, efficacy, and challenges of SMC in Niger between 2013 and 2022, analyzing its impact on malaria morbidity and mortality. Materials and methods The PRISMA guidelines were used to ensure a rigorous and comprehensive recording of the systematic review process. Through searches in five different databases, articles were imported into Zotero software, then transferred to the Covidence application, where data processing was carried out. The selected articles were independently evaluated by two reviewers. These included studies that assessed coverage, malaria incidence, and the impact of SMC. Studies published in French and English were included. Data extraction from the included studies was performed, and a quality assessment was conducted, including an evaluation of the risk of bias. Results Among the six studies, three assessed SMC coverage in all eight regions of Niger while also evaluating side effects. They showed high overall coverage but low coverage in some areas. Another study examined the impact in terms of the incidence of complicated malaria, malaria-related hospitalization, and mortality. Another publication revealed that antibody responses against the blood and pre-erythrocytic stages of P. falciparum were higher in the area where SMC was implemented. Conclusions This study demonstrates that SMC has a significant impact on reducing malaria incidence. Although there is high overall coverage, variations exist, particularly in hard-to-reach areas. Few adverse events were reported. However, very few studies are available, highlighting the need for additional research in Niger to better understand this strategy.
- Open Access
- 22 April 2026
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 53 (171)
Cinquième cycle mensuel de la chimioprévention du paludisme saisonnier chez les enfants de 3 à 59 mois dans la région de Zinder, Niger: approche de son impact
L'ajout d'un cinquième cycle mensuel à la chimioprévention saisonnière du paludisme (CSP) a été proposé afin de prolonger la protection pendant les saisons de transmission prolongées au Sahel. Cette étude a évalué l'effet de l'introduction d'un cinquième cycle de CSP sur l'incidence du paludisme et sur l'utilisation des services de diagnostic et de traitement du paludisme dans le district sanitaire de Takieta, au Niger. Nous avons mené une étude quasi expérimentale, non randomisée, avant-après, avec un groupe de comparaison (conception « ici-ailleurs ») en utilisant les données de santé courantes de 19 centres de santé intégrés répartis dans deux districts sanitaires entre 2020 et 2023. Neuf centres de santé ont mis en œuvre cinq cycles mensuels de SMC (SMC5), tandis que dix centres de santé ont poursuivi la stratégie standard à quatre cycles. Les données ont été extraites du système national d'information sanitaire. Un modèle à effets fixes de différence dans les différences (DiD) a été appliqué pour estimer l'impact du cinquième cycle de SMC sur l'incidence du paludisme, l'utilisation des tests de diagnostic rapide (TDR), la positivité des TDR et la consommation de combinaisons thérapeutiques à base d'artémisinine (ACT). L'introduction d'un cinquième cycle de SMC a été associée à une réduction significative de l'incidence du paludisme, correspondant à une diminution de 2,44 cas pour 1 000 habitants pendant la période d'intervention. Cette réduction s'est accompagnée d'une amélioration de 2,99 % des performances des services de soins et d'une baisse significative des taux de positivité des TDR (p = 0,003). Cependant, les coefficients de différence dans les différences pour la consommation de TDR (158,59) et la consommation d'ACT (153,05) n'étaient pas statistiquement significatifs, ce qui indique que le SMC5 n'a pas eu d'impact mesurable sur la réduction de l'utilisation des tests diagnostiques ou des traitements antipaludiques. L'ajout d'un cinquième cycle mensuel de chimioprévention saisonnière du paludisme a été associé à une réduction de l'incidence du paludisme dans les districts étudiés pendant la période d'intervention. Cependant, aucune preuve d'une réduction correspondante de la consommation de TDR ou d'ACT n'a été trouvée. Ces résultats suggèrent que l'extension de la couverture de la SMC d'un mois supplémentaire peut réduire la charge du paludisme sans modifier de manière significative l'utilisation des services de diagnostic ou de traitement dans les établissements de santé.
- 22 April 2026
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 53 (171)
Open AccessCinquième cycle mensuel de la chimioprévention du paludisme saisonnier chez les enfants de 3 à 59 mois dans la région de Zinder, Niger: approche de son impact
L'ajout d'un cinquième cycle mensuel à la chimioprévention saisonnière du paludisme (CSP) a été proposé afin de prolonger la protection pendant les saisons de transmission prolongées au Sahel. Cette étude a évalué l'effet de l'introduction d'un cinquième cycle de CSP sur l'incidence du paludisme et sur l'utilisation des services de diagnostic et de traitement du paludisme dans le district sanitaire de Takieta, au Niger. Nous avons mené une étude quasi expérimentale, non randomisée, avant-après, avec un groupe de comparaison (conception « ici-ailleurs ») en utilisant les données de santé courantes de 19 centres de santé intégrés répartis dans deux districts sanitaires entre 2020 et 2023. Neuf centres de santé ont mis en œuvre cinq cycles mensuels de SMC (SMC5), tandis que dix centres de santé ont poursuivi la stratégie standard à quatre cycles. Les données ont été extraites du système national d'information sanitaire. Un modèle à effets fixes de différence dans les différences (DiD) a été appliqué pour estimer l'impact du cinquième cycle de SMC sur l'incidence du paludisme, l'utilisation des tests de diagnostic rapide (TDR), la positivité des TDR et la consommation de combinaisons thérapeutiques à base d'artémisinine (ACT). L'introduction d'un cinquième cycle de SMC a été associée à une réduction significative de l'incidence du paludisme, correspondant à une diminution de 2,44 cas pour 1 000 habitants pendant la période d'intervention. Cette réduction s'est accompagnée d'une amélioration de 2,99 % des performances des services de soins et d'une baisse significative des taux de positivité des TDR (p = 0,003). Cependant, les coefficients de différence dans les différences pour la consommation de TDR (158,59) et la consommation d'ACT (153,05) n'étaient pas statistiquement significatifs, ce qui indique que le SMC5 n'a pas eu d'impact mesurable sur la réduction de l'utilisation des tests diagnostiques ou des traitements antipaludiques. L'ajout d'un cinquième cycle mensuel de chimioprévention saisonnière du paludisme a été associé à une réduction de l'incidence du paludisme dans les districts étudiés pendant la période d'intervention. Cependant, aucune preuve d'une réduction correspondante de la consommation de TDR ou d'ACT n'a été trouvée. Ces résultats suggèrent que l'extension de la couverture de la SMC d'un mois supplémentaire peut réduire la charge du paludisme sans modifier de manière significative l'utilisation des services de diagnostic ou de traitement dans les établissements de santé.
- Open Access
- 30 May 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 539
Study of the coverage and the impact of the chemoprevention of seasonal malaria in Niger from 2013 to 2022: systematic review
Purpose Malaria remains a public health problem in Niger, especially among children under the age of five. To combat this scourge, since 2012, the World Health Organization (WHO) has recommended seasonal malaria chemoprevention (SMC), a strategy based on the administration of sulfadoxine-pyrimethamine and amodiaquine (SP-AQ) during the period of high transmission. This systematic review assesses the coverage, efficacy, and challenges of SMC in Niger between 2013 and 2022, analyzing its impact on malaria morbidity and mortality. Materials and methods The PRISMA guidelines were used to ensure a rigorous and comprehensive recording of the systematic review process. Through searches in five different databases, articles were imported into Zotero software, then transferred to the Covidence application, where data processing was carried out. The selected articles were independently evaluated by two reviewers. These included studies that assessed coverage, malaria incidence, and the impact of SMC. Studies published in French and English were included. Data extraction from the included studies was performed, and a quality assessment was conducted, including an evaluation of the risk of bias. Results Among the six studies, three assessed SMC coverage in all eight regions of Niger while also evaluating side effects. They showed high overall coverage but low coverage in some areas. Another study examined the impact in terms of the incidence of complicated malaria, malaria-related hospitalization, and mortality. Another publication revealed that antibody responses against the blood and pre-erythrocytic stages of P. falciparum were higher in the area where SMC was implemented. Conclusions This study demonstrates that SMC has a significant impact on reducing malaria incidence. Although there is high overall coverage, variations exist, particularly in hard-to-reach areas. Few adverse events were reported. However, very few studies are available, highlighting the need for additional research in Niger to better understand this strategy.
- 30 May 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 539
Open AccessStudy of the coverage and the impact of the chemoprevention of seasonal malaria in Niger from 2013 to 2022: systematic review
Purpose Malaria remains a public health problem in Niger, especially among children under the age of five. To combat this scourge, since 2012, the World Health Organization (WHO) has recommended seasonal malaria chemoprevention (SMC), a strategy based on the administration of sulfadoxine-pyrimethamine and amodiaquine (SP-AQ) during the period of high transmission. This systematic review assesses the coverage, efficacy, and challenges of SMC in Niger between 2013 and 2022, analyzing its impact on malaria morbidity and mortality. Materials and methods The PRISMA guidelines were used to ensure a rigorous and comprehensive recording of the systematic review process. Through searches in five different databases, articles were imported into Zotero software, then transferred to the Covidence application, where data processing was carried out. The selected articles were independently evaluated by two reviewers. These included studies that assessed coverage, malaria incidence, and the impact of SMC. Studies published in French and English were included. Data extraction from the included studies was performed, and a quality assessment was conducted, including an evaluation of the risk of bias. Results Among the six studies, three assessed SMC coverage in all eight regions of Niger while also evaluating side effects. They showed high overall coverage but low coverage in some areas. Another study examined the impact in terms of the incidence of complicated malaria, malaria-related hospitalization, and mortality. Another publication revealed that antibody responses against the blood and pre-erythrocytic stages of P. falciparum were higher in the area where SMC was implemented. Conclusions This study demonstrates that SMC has a significant impact on reducing malaria incidence. Although there is high overall coverage, variations exist, particularly in hard-to-reach areas. Few adverse events were reported. However, very few studies are available, highlighting the need for additional research in Niger to better understand this strategy.